Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma

Stack, Anthony; Levy, Isaac

doi:10.1002/ccr3.2142

Cited by 13 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their patient remained in complete remission after 3 year follow up. Subsequently, we reported a patient with significant extracapsular invasion, involving both the chest wall and pleura (Stage III) [ 15 ]. Our patient received 18 cycles of brentuximab vedotin monotherapy after surgical explantation and radiation therapy.…”

Section: Brentuximab Vedotinmentioning

confidence: 99%

“…Interest has been given to the utilization of the novel anti-CD30 antibody-drug conjugate, brentuximab vedotin; however, until recently, its use has only been described in case reports and small series as an adjuvant for limited stage disease or as combination therapy with conventional chemotherapy for advanced disease [12][13][14]. Recently, we published a case report describing the successful application of brentuximab vedotin as monotherapy after surgical explantation and radiation for a case of advanced, unresectable BIA-ALCL [15]. In the current review, we will provide and in-depth discussion of the current literature on BIA-ALCL and the evidence supporting the use of brentuximab vedotin in treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin

Stack

Ali

Khan

2020

Journal of Cellular Immunology

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma is a recently recognized complication of textured breast implants. It typically presents as unilateral peri-implant swelling approximately 7-10 years after implantation. While the course is usually indolent, breast implant-associated anaplastic large cell lymphoma may form a locally invasive mass and metastasize to regional lymph nodes or beyond to distant sites. Surgical excision has been well established as the standard of care for localized disease; however, guidelines directing management of advanced, recurrent or unresectable disease are based on limited and extrapolated evidence. The CD30-targeting immunoconjugate, brentuximab vedotin, has been utilized in this setting, typically in combination with chemotherapy. We recently reported a patient with unresectable breast implant-associated anaplastic large cell lymphoma who was treated with brentuximab vedotin monotherapy and has now sustained complete remission for 2.6 years. Herein, we provide an up-to-date review of the epidemiology, pathogenesis, clinical features, diagnosis and management of breast implant associated anaplastic large cell lymphoma with emphasis on the role of brentuximab vedotin.

show abstract

Section: Brentuximab Vedotinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin

Stack

Ali

Khan

2020

Journal of Cellular Immunology

View full text Add to dashboard Cite

show abstract

“…Brentuximab vedotin también se ha utilizado con éxito en el tratamiento de LACG-AIM irresecable. (15) La paciente se mantiene en revisiones periódicas a cargo de los Servicios de Hematología y Cirugía Plástica.…”

Section: Caso Clínicounclassified

Limitaciones diagnósticas de las determinaciones inmunohistoquímicas preoperatorias en el linfoma anaplásico de células grandes asociado a implante mamario (LACG-AIM)

Casado-Pérez

Chicote

Franjo

et al. 2019

Cir. plást. iberolatinoam.

View full text Add to dashboard Cite

Limitaciones diagnósticas de las determinaciones inmunohistoquímicas preoperatorias en el linfoma anaplásico de células grandes asociado a implante mamario (LACG-AIM) Diagnostic limitations of preoperative immunohistochemical determinations in breast implant associated anaplastic large cell lymphoma (BIA-ALCL) Original /Caso clínico CIRUGÍA MAMARIAPalabras clave Linfoma anaplásico de células gigantes, Implantes mamarios, Prótesis mamarias, Seroma tardío.Nivel de evidencia científica 5c Diagnóstico Recibido (esta versión)

show abstract

“…An estimated 43,390 breast augmentation surgeries (86,780 implants) and 1486 breast implant reconstructions are performed annually in Colombia, compared with approximately 217,000 in Brazil and 331,000 in the United States. 20 Although sporadic cases with BIA-ALCL have been reported from Colombia, 21 there are no reports evaluating the incidence of BIA-ALCL epidemiology or outcomes in Colombia or any other Latin American country. Therefore, a National Joint Multidisciplinary Committee was formed between the Colombian scientific societies of Mastology, Plastic Surgery, the Colombian Society of Hematology and Oncology (Asociacion Colombiana de Hemato Oncologia; ACHO), and The National Food and Drug Surveillance Institute (Invima) to track national cases within this population and to develop a consensus to standardize education on disease awareness and improve the identification and diagnosis of patients with BIA-ALCL (Fig.…”

Section: Introductionmentioning

confidence: 99%

Breast Implant–associated Anaplastic Large Cell Lymphoma in Colombia: Report of a Multidisciplinary National Registry

Gomez¹,

Abad

Duque

et al. 2020

Plastic and Reconstructive Surgery - Global Open

View full text Add to dashboard Cite

Background: An estimated 43,390 breast augmentation surgeries (86,780 implants) and 1486 breast implant reconstructions are performed annually in Colombia, representing the second-most breast surgery destination in South America, the fourth in the western hemisphere, and the fifth country worldwide. No previous reports have evaluated the incidence of breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) epidemiology or outcomes in a Hispanic population. Published data on the incidence of this disease in Colombia are unknown; therefore, a National Joint Multidisciplinary Committee was developed between the Colombian scientific societies of Mastology, Plastic Surgery, Hemato-Oncology, and the Invima (The National Food and Drug Surveillance Institute) to track national cases of BIA-ALCL. Materials and Methods: We performed a retrospective review (survey-based study) of historical cases since 2011–2019, and a prospective collection of all patients with a confirmed World Health Organization diagnosis of BIA-ALCL identified in a newly established National Registry of BIA-ALCL. The trial was approved by Institutional Review Board (IRB). Results: Eighteen cases of BIA-ALCL were identified in Colombia between 2011 and 2019. Hundred percent developed as sequelae of textured implants. Six patients (33.3%) presented either a peri-implant capsule mass or axillary lymph node involvement. Seven (38.9%) required adjuvant chemotherapy most commonly with CHOP regimen. Different brands of implants were associated with our cases. One death (5.6%) was attributed to BIA-ALCL, and one (5.6%) case displayed with relapsed with bone marrow involvement requiring a bone marrow transplantation. Six cases (33.3%) were identified with advanced stage (IIB-IV). Disease-free survival of 92.3% was achieved at 30.8-month follow-up. Conclusions: Colombia has one of the highest volumes of breast surgery and use of textured surface breast implants in the world. This study is the initial report of an implant registry in South America. A high proportion of advanced disease may be a consequence of delayed presentation, lack of disease awareness, and timely access to tertiary cancer centers for diagnosis and treatment. Brands other than Allergan and Mentor were found to be associated with BIA-ALCL in our study.

show abstract

Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma

Cited by 13 publications

References 17 publications

Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin

Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin

Limitaciones diagnósticas de las determinaciones inmunohistoquímicas preoperatorias en el linfoma anaplásico de células grandes asociado a implante mamario (LACG-AIM)

Breast Implant–associated Anaplastic Large Cell Lymphoma in Colombia: Report of a Multidisciplinary National Registry

Contact Info

Product

Resources

About